Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 11, 2025Journal of Nuclear Medicine

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSteven P. RoweBSBrian ShuchMBMark W. Ball

Discussion

Loading...

Member takes

Overview

This guideline outlines how molecular imaging improves risk stratification for renal masses, highlighting CAIX and mitochondrial imaging techniques.

Key Points

  • Molecular imaging improves risk stratification for renal masses, enhancing patient decision-making.
  • Agents targeting CAIX, notably 89Zr-girentuximab, are pivotal in identifying clear cell renal cell carcinoma.
  • Mitochondrial imaging agents, such as 99mTc-sestamibi, differentiate benignant oncocytomas from ccRCC.
  • AI-driven biomarker discovery is set to advance the field of renal mass characterization further.

Cite This Study

Rowe et al. (2025) studied this question.

synapsesocial.com/papers/68ea72339f1bd4df558cec09https://doi.org/10.2967/jnumed.125.271332
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma.2025
  2. 2Renal Mass Biopsy in the Management of Small Renal Masses2024
  3. 3MRI in combination with Technetium‐99m‐sestamibi single‐photon emission CT/CT: a novel diagnostic algorithm to maximise the characterisation of small renal masses2025
  4. 4A systematic review of renal mass biopsy: what evidence supports its use (or omission)?2025
  5. 5Artificial Intelligence in the Detection, Characterization, and Management of Renal Masses: A Narrative Review2026